Product Information
Registration Status: ActiveSIN15249P
MILRINONE-AFT CONCENTRATED SOLUTION FOR INJECTION 10MG/10ML is approved to be sold in Singapore with effective from 2017-05-26. It is marketed by BAXTER HEALTHCARE (ASIA) PTE LTD, with the registration number of SIN15249P.
This product contains Milrinone 1mg/mL in the form of INJECTION, SOLUTION, CONCENTRATE. It is approved for INTRAVENOUS use.
This product is manufactured by Claris Injectables LTD in INDIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the ionotropic potency of amrinone. [PubChem]
Indication
Indicated for the treatment of congestive heart failure.
Mechanism of Action
Milrinone inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrinone also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.
Pharmacokinetics
- Absorption
- Milrinone is rapidly and almost completely absorbed after oral administration. Bioavailability is 92% (in healthy volunteers).
- Distribution
- * 0.38 liters/kg [intravenous injections of 12.5 mcg/kg to 125 mcg/kg to congestive heart failure patients] * 0.45 liters/kg [intravenous infusions of 0.20 mcg/kg/min to 0.70 mcg/kg/min to congestive heart failure patients]
- Metabolism
- There are five metabolites but the O-glucuronide represents the major pathway of biotransformation.
- Elimination
Clearance
* 0.13 L/kg/hr [congestive heart failure patients, following IV injections of 12.5 mcg/kg to 125 mcg/kg] * 0.14 L/kg/hr [congestive heart failure patients, following infusions of 0.2 mcg/kg/min to 0.7 mcg/kg/min]
Toxicity
LD50 = 0.3 mg/L in rats
Active Ingredient/Synonyms
1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile | Milrinona | Milrinone | Milrinonum | Milrinone |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.